Back to Catalog
Cytospire Therapeutics
cytospire
Pan gamma delta T cell engager antibodies for solid tumor oncology.
Total Funding
$83M
sector:biotech
stage:series_a
oncology
preclinical
4BIO-Capital
Abingworth
Servier-strategic
gamma-delta-t-cell
bispecific-antibody
immuno-oncology
UK-biotech
Full Profile Gated
Register as a Qualified Purchaser to access the full profile of Cytospire Therapeutics, including financial analysis, competitive landscape, and investment thesis.